AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

GENETIC TECHNOLOGIES LIMITED Board/Management Information 2019

Jul 8, 2019

65022_rns_2019-07-08_143899b4-0742-48db-8bc3-176ff338f962.pdf

Board/Management Information

Open in viewer

Opens in your device viewer

ASX Market Announcement

==> picture [151 x 50] intentionally omitted <==

9[th] July 2019

Resignation of Non Executive Director – Mr Sam Lee

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”), advises that Non-Executive Director, Mr Sam Lee has resigned as a Director of the Company effective immediately.

About Genetic Technologies Limited

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead products GeneType for Breast Cancer for nonhereditary breast cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class.

Genetic Technologies is developing a pipeline of risk assessment products.

FOR FURTHER INFORMATION PLEASE CONTACT

Mr Paul Viney Company Secretary Genetic Technologies Limited +61438072616